Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944388 | 0.87 | GCGR (0.43) | GCGR | |
| SCHEMBL14400742 | 0.82 | GCGR (0.47) | GCGR | |
| SCHEMBL7920817 | 0.82 | GCGR (0.46) | GCGR | |
| SCHEMBL10129581 | 0.80 | DHODH (0.44) | GCGR | |
| SCHEMBL4449474 | 0.79 | GCGR (0.63) | GCGR | |
| SCHEMBL12912572 | 0.78 | RXFP1 (0.40) | GCGR | |
| SCHEMBL27984907 | 0.78 | KMT2A (0.51) | — | |
| SCHEMBL14400636 | 0.77 | MAPT (0.37) | GCGR | |
| SCHEMBL8949822 | 0.77 | GCGR (0.88) | GCGR | |
| SCHEMBL16429685 | 0.77 | GCGR (0.57) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872012-B2 | Pyrimidinone compounds and preparation and use thereof | Zhejiang Hisun Pharma Co., Ltd. (CN) | 2011-01-18 | — | — | US | disclosed |
| US-7872012-B2 | Pyrimidinone compounds and preparation and use thereof | Zhejiang Hisun Pharma Co., Ltd. (CN) | 2011-01-18 | — | — | US | disclosed |
| EP-1845092-B1 | PYRIMIDINONE COMPOUNDS, THEIR PREPARATION AND USE THEREOF | YAO HUI (CN) | 2010-09-01 | — | — | EP | disclosed |
| US-20080280930-A1 | Pyrimidinone Compounds and Preparation and Use Thereof | Yao, Hui (CN) | 2008-11-13 | — | — | US | disclosed |
| US-20080280930-A1 | Pyrimidinone Compounds and Preparation and Use Thereof | Yao, Hui (CN) | 2008-11-13 | — | — | US | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1845092-A1 | PYRIMIDINONE COMPOUNDS, THEIR PREPARATION AND USE THEREOF | Yao, Hui (CN) | 2007-10-17 | — | — | EP | disclosed |
| EP-1845092-A1 | PYRIMIDINONE COMPOUNDS, THEIR PREPARATION AND USE THEREOF | Yao, Hui (CN) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280930-A1 | Pyrimidinone Compounds and Preparation and Use Thereof | HMGCR, PSEN1, DHPS | GCGR 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.